Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (12): 1141-1145.DOI: 10.3969/j.issn.1673-8640.2022.12.008
Previous Articles Next Articles
ZHENG Jiahua, YAO Yanying(), GAO Qingling, DONG Ye
Received:
2021-04-09
Revised:
2022-03-08
Online:
2022-12-30
Published:
2023-02-02
Contact:
YAO Yanying,E-mail:YAOYYDOC@163.com。
CLC Number:
ZHENG Jiahua, YAO Yanying, GAO Qingling, DONG Ye. Predictive values of Lp(a) and apoB/apoA-1 ratio for the occurrence of MACE in patients with AMI after interventional therapy[J]. Laboratory Medicine, 2022, 37(12): 1141-1145.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.12.008
组别 | 例数 | 男性 | 年龄/岁 | 发病至介入治疗时间/h | 入院时心率/(次/min) | 高血压史/ [例(%)] | 糖尿病史/ [例(%)] | |||
---|---|---|---|---|---|---|---|---|---|---|
MACE组 | 47 | 27(57.45) | 61.49±6.83 | 3.27±0.94 | 86±12 | 13(27.66) | 8(17.02) | |||
无MACE组 | 153 | 102(66.67) | 58.72±8.90 | 2.96±1.03 | 84±14 | 49(32.03) | 38(24.84) | |||
统计值 | 1.335 | 1.962 | 1.841 | 0.895 | 0.321 | 1.240 | ||||
P值 | 0.248 | 0.051 | 0.067 | 0.372 | 0.571 | 0.266 | ||||
组别 | 梗死部位/[例(%)] | HDL-C/(mmol/L) | LDL-C/(mmol/L) | NT-proBN/ (pg/mL) | LVEF/% | |||||
前壁梗死 | 下壁梗死 | 正后壁梗死 | 前间壁梗死 | |||||||
MACE组 | 18(38.30) | 13(27.66) | 7(14.89) | 9(19.15) | 1.20±0.35 | 3.24±0.57 | 3 816.59±1 539.68 | 43.72±7.19 | ||
无MACE组 | 74(48.37) | 27(17.65) | 30(19.61) | 22(14.38) | 1.18±0.34 | 2.62±0.71 | 1 929.84±567.59 | 52.83±5.01 | ||
统计值 | 3.554 | 0.350 | 5.467 | 12.664 | 9.767 | |||||
P值 | 0.314 | 0.727 | <0.001 | <0.001 | <0.001 | |||||
组别 | BMI/ (kg/m2) | cTnI/ (ng/mL) | 血糖/ (mmol/L) | HbA1c/% | TC/ (mmol/L) | TG/ (mmol/L) | CRP/ (mg/L) | |||
MACE组 | 23.75±2.78 | 6.28±2.07 | 7.28±1.25 | 8.25±2.14 | 4.62±0.74 | 1.78±0.31 | 13.89±5.26 | |||
无MACE组 | 23.36±3.02 | 5.74±1.69 | 6.92±1.19 | 7.89±2.25 | 4.58±0.65 | 1.69±0.27 | 12.94±4.98 | |||
统计值 | 0.780 | 1.814 | 1.793 | 0.970 | 0.357 | 1.929 | 1.129 | |||
P值 | 0.436 | 0.071 | 0.075 | 0.333 | 0.722 | 0.055 | 0.260 |
组别 | 例数 | 男性 | 年龄/岁 | 发病至介入治疗时间/h | 入院时心率/(次/min) | 高血压史/ [例(%)] | 糖尿病史/ [例(%)] | |||
---|---|---|---|---|---|---|---|---|---|---|
MACE组 | 47 | 27(57.45) | 61.49±6.83 | 3.27±0.94 | 86±12 | 13(27.66) | 8(17.02) | |||
无MACE组 | 153 | 102(66.67) | 58.72±8.90 | 2.96±1.03 | 84±14 | 49(32.03) | 38(24.84) | |||
统计值 | 1.335 | 1.962 | 1.841 | 0.895 | 0.321 | 1.240 | ||||
P值 | 0.248 | 0.051 | 0.067 | 0.372 | 0.571 | 0.266 | ||||
组别 | 梗死部位/[例(%)] | HDL-C/(mmol/L) | LDL-C/(mmol/L) | NT-proBN/ (pg/mL) | LVEF/% | |||||
前壁梗死 | 下壁梗死 | 正后壁梗死 | 前间壁梗死 | |||||||
MACE组 | 18(38.30) | 13(27.66) | 7(14.89) | 9(19.15) | 1.20±0.35 | 3.24±0.57 | 3 816.59±1 539.68 | 43.72±7.19 | ||
无MACE组 | 74(48.37) | 27(17.65) | 30(19.61) | 22(14.38) | 1.18±0.34 | 2.62±0.71 | 1 929.84±567.59 | 52.83±5.01 | ||
统计值 | 3.554 | 0.350 | 5.467 | 12.664 | 9.767 | |||||
P值 | 0.314 | 0.727 | <0.001 | <0.001 | <0.001 | |||||
组别 | BMI/ (kg/m2) | cTnI/ (ng/mL) | 血糖/ (mmol/L) | HbA1c/% | TC/ (mmol/L) | TG/ (mmol/L) | CRP/ (mg/L) | |||
MACE组 | 23.75±2.78 | 6.28±2.07 | 7.28±1.25 | 8.25±2.14 | 4.62±0.74 | 1.78±0.31 | 13.89±5.26 | |||
无MACE组 | 23.36±3.02 | 5.74±1.69 | 6.92±1.19 | 7.89±2.25 | 4.58±0.65 | 1.69±0.27 | 12.94±4.98 | |||
统计值 | 0.780 | 1.814 | 1.793 | 0.970 | 0.357 | 1.929 | 1.129 | |||
P值 | 0.436 | 0.071 | 0.075 | 0.333 | 0.722 | 0.055 | 0.260 |
组别 | 例数 | Lp(a)/(mg/L) | apo B/apo A-1比值 |
---|---|---|---|
MACE组 | 47 | 445.7(342.5~584.1) | 1.32±0.31 |
无MACE组 | 153 | 286.1(176.9~372.8) | 0.87±0.29 |
统计值 | 9.944 | 9.154 | |
P值 | <0.001 | <0.001 |
组别 | 例数 | Lp(a)/(mg/L) | apo B/apo A-1比值 |
---|---|---|---|
MACE组 | 47 | 445.7(342.5~584.1) | 1.32±0.31 |
无MACE组 | 153 | 286.1(176.9~372.8) | 0.87±0.29 |
统计值 | 9.944 | 9.154 | |
P值 | <0.001 | <0.001 |
项目 | NT-proBNP | LDL-C | LVEF | |||||
---|---|---|---|---|---|---|---|---|
r值 | P值 | r值 | P值 | r值 | P值 | |||
Lp(a) | 0.659 | <0.001 | 0.738 | <0.001 | -0.578 | <0.001 | ||
apo B/apo A-1比值 | 0.631 | <0.001 | 0.715 | <0.001 | -0.493 | <0.001 |
项目 | NT-proBNP | LDL-C | LVEF | |||||
---|---|---|---|---|---|---|---|---|
r值 | P值 | r值 | P值 | r值 | P值 | |||
Lp(a) | 0.659 | <0.001 | 0.738 | <0.001 | -0.578 | <0.001 | ||
apo B/apo A-1比值 | 0.631 | <0.001 | 0.715 | <0.001 | -0.493 | <0.001 |
项目 | β值 | 标准误 | Wald值 | P值 | HR值(95%CI) |
---|---|---|---|---|---|
Lp(a) | 0.853 | 0.250 | 11.640 | <0.001 | 2.347(1.459~3.774) |
apo B/apo A-1比值 | 0.907 | 0.241 | 14.155 | <0.001 | 2.476(1.561~3.928) |
项目 | β值 | 标准误 | Wald值 | P值 | HR值(95%CI) |
---|---|---|---|---|---|
Lp(a) | 0.853 | 0.250 | 11.640 | <0.001 | 2.347(1.459~3.774) |
apo B/apo A-1比值 | 0.907 | 0.241 | 14.155 | <0.001 | 2.476(1.561~3.928) |
指标 | AUC(95%CI) | P值 | 最佳临界值 | 敏感性/% | 特异性/% |
---|---|---|---|---|---|
Lp(a) | 0.798(0.735~0.851) | <0.001 | 385.7 mg/L | 72.34 | 81.70 |
apo B/apo A-1比值 | 0.821(0.760~0.871) | <0.001 | 1.03 | 78.72 | 69.93 |
联合检测模型 | 0.898(0.848~0.937) | <0.001 | 39.65 | 82.98 | 87.97 |
指标 | AUC(95%CI) | P值 | 最佳临界值 | 敏感性/% | 特异性/% |
---|---|---|---|---|---|
Lp(a) | 0.798(0.735~0.851) | <0.001 | 385.7 mg/L | 72.34 | 81.70 |
apo B/apo A-1比值 | 0.821(0.760~0.871) | <0.001 | 1.03 | 78.72 | 69.93 |
联合检测模型 | 0.898(0.848~0.937) | <0.001 | 39.65 | 82.98 | 87.97 |
1 | 孟萌, 魏佳丽, 潘红, 等. 血清HMGB1、sTLT-1水平对经皮冠状动脉介入治疗急性心肌梗死患者预后的影响[J]. 中国现代医学杂志, 2019, 29(24):38-43. |
2 | 王素玲, 贾永平, 何丽娇. GRACE评分联合血清Lp-PLA2 NT-proBNP水平监测在急性心肌梗死患者PCI术后MACE事件预测中的应用[J]. 河北医学, 2019, 25(5):737-742. |
3 | 廉铮, 吕峰峰, 王佳旺, 等. RDW联合SYNTAXⅡ积分对急性心肌梗死患者行PCI后发生不良心血管事件的预测价值[J]. 山东医药, 2020, 60(4):66-69. |
4 | 王蓓丽, 李辉军, 伍严安, 等. 血清生化指标与冠心病患者冠状动脉狭窄程度的相关性[J]. 检验医学, 2020, 35(1):6-10. |
5 | 韩秀, 田雨灵, 卓小桢, 等. 载脂蛋白A、载脂蛋白B/载脂蛋白A比值与冠脉病变严重程度的相关性[J]. 西安交通大学学报(医学版), 2019, 40(2):255-258. |
6 | 石艳璞, 曹晔萱, 靳景璐, 等. 血浆脂蛋白(a)浓度与青年人群冠心病关系的横断面研究[J]. 中国循环杂志, 2020, 35(4):343-348. |
7 | TIAN Y F, ZHOU Y P, ZHONG C K, et al. C-reactive protein level,apolipoprotein B-to-apolipoprotein A-1 ratio,and risks of ischemic stroke and coronary heart disease among Inner Mongolians in China[J]. Biomed Environ Sci, 2016, 29(7):467-474. |
8 |
OZAKI Y, HARA H, ONUMA Y, et al. CVIT expert consensus document on primary percutaneous coronary intervention(PCI) for acute myocardial infarction(AMI) update 2022[J]. Cardiovasc Interv Ther, 2022, 37(1):1-34.
DOI URL |
9 | BITTNER V A, SZAREK M, AYLWARD P E, et al. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome[J]. J Am Coll Cardiol, 2020, 75(2):133-144. |
10 |
WAISSI F, DEKKER M, TIMMERMAN N, et al. Elevated Lp(a) [Lipoprotein(a)] levels increase risk of 30-day major adverse cardiovascular events in patients following carotid endarterectomy[J]. Stroke, 2020, 51(10):2972-2982.
DOI URL |
11 | 马煜盛, 饶甲环, 龙洁旎, 等. 脂蛋白(a)与冠心病患者临床稳定性及冠状动脉狭窄程度的关系[J]. 南方医科大学学报, 2019, 39(2):235-240. |
12 | 姚心琪, 张秀兰. 血浆脂蛋白a与冠状动脉粥样硬化病变程度相关性研究[J]. 中国药物与临床, 2019, 19(5):698-701. |
13 |
HOLL M J, VAN DEN BOS E J, VAN DOMBURG R T, et al. NT-proBNP is associated with mortality and adverse cardiac events in patients with atrial fibrillation presenting to the emergency department[J]. Clin Cardiol, 2018, 41(3):400-405.
DOI PMID |
14 | 陈颖, 祝振忠. 高LDL-C血症与急性心肌梗死病人阿司匹林反应性的相关性研究[J]. 陕西医学杂志, 2017, 46(4):496-497. |
15 |
ZHU Y M, VERMA S, FUNG M, et al. Association of apolipoproteins B and A-1 with markers of vascular health or cardiovascular events[J]. Can J Cardiol, 2017, 33(10):1305-1311.
DOI PMID |
16 | 黄恒贵. 心电图QRS波时限与血清ApoB/ApoA-Ⅰ比值在冠心病患者冠脉病变严重程度评估中的价值[J]. 武汉大学学报(医学版), 2020, 41(1):114-118. |
17 | 李林芝, 常颖. 平均血小板体积/血小板计数、载脂蛋白B/A1与高血压患者动态动脉硬化指数的相关性[J]. 中华高血压杂志, 2019, 27(5):471-473. |
18 |
JELLINGER P S, HANDELSMAN Y, ROSENBLIT P D, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease[J]. Endocr Pract, 2017, 23(Suppl 2):1-87.
DOI PMID |
19 | 董茜, 韩晓涛, 陈维君, 等. 冠心病患者血清ApoB/A-1比值、Hcy水平变化及临床意义[J]. 中国循证心血管医学杂志, 2019, 11(8):968-970. |
20 | 赵永娟, 王军, 季韧, 等. 血清载脂蛋白B与载脂蛋白A-1比值与脑卒中的相关性及其预测价值[J]. 神经病学与神经康复学杂志, 2019, 15(2):89-94. |
[1] | FU Yi, YANG Xuesong, JIN Ligang, ZHAI Hongli, JIN Xiaoling. Correlation between small and dense low-density lipoprotein cholesterol and acute coronary syndrome with the occurrence of long-term adverse cardiovascular events [J]. Laboratory Medicine, 2023, 38(9): 878-883. |
[2] | WANG Yang, MO Huifang, SHEN Ruojian, SHEN Yifeng, WANG Beili, PAN Baishen, GUO Wei. Analysis on the difference of lipoprotein(a) particle concentration and mass concentration in certain disease states [J]. Laboratory Medicine, 2023, 38(5): 405-412. |
[3] | XING Baobao, CAO Yinfang. Predictive value of sd-LDL-C/LDL-C ratio for in-stent restenosis in patients with AMI after interventional therapy [J]. Laboratory Medicine, 2023, 38(10): 941-945. |
[4] | PAN Wenqi, LU Lin. Relationship between Vasostatin-2 and the occurrence of chronic heart failure and its prognosis in patients with myocardial infarction [J]. Laboratory Medicine, 2022, 37(7): 623-627. |
[5] | MA Jianguo, ZHU Xiaolin, DING Yongguang, YIN Meng, LI Hongchun. Predictive values of red blood cell distribution width and myocardial markers for acute myocardial infarction in patients with CAS [J]. Laboratory Medicine, 2022, 37(12): 1164-1168. |
[6] | ZHANG Xilin, SHEN Yifeng, ZHU Jing, ZHANG Chunyan, SHAO Wenqi, WANG Beili, GUO Wei. Roles of AST,m-AST and m-AST/AST in preoperative and postoperative evaluation of patients with CHD and AMI [J]. Laboratory Medicine, 2021, 36(5): 471-476. |
[7] | DU Kun, YAN Jianhua, CHEN Ming, YANG Junyao, ZHANG Guanghui. Role of risk stratification and prognosis of sST2 in acute coronary syndrome patients after percutaneous coronary intervention [J]. Laboratory Medicine, 2021, 36(10): 1020-1025. |
[8] | ZOU Jihua, ZHANG Wei, SHEN Min, ZHANG Man, TU Minmin, WANG Huimin, ZHOU Houqing. Research progress in the separation of serum lipoprotein subfractions and lipoprotein(a) [J]. Laboratory Medicine, 2021, 36(10): 1078-1086. |
[9] | LI Ying, CAI Qin, ZHANG Weiwei, WANG Baoli, LI Chenhui. Clinical role of serum ICTP and MMP-2 in acute myocardial infarction [J]. Laboratory Medicine, 2020, 35(12): 1272-1276. |
[10] | MA Xiuqing, JIA Haiju, QIN Huiping, MA Huiying, YANG Xingtang, QI Yanxia, LI Shengmei, WANG Chunwei, HE Yujuan. Changes of IL-6 and other 7 indexes in patients with acute cerebral infarction in Qinghai [J]. Laboratory Medicine, 2019, 34(9): 821-825. |
[11] | DING Hui, LI Zhumeng, WANG Yin, WANG Dong, SHENG Huiming. Analysis of serum lipoprotein (a) and homocysteine levels in patients with acute coronary syndrome [J]. Laboratory Medicine, 2019, 34(12): 1082-1087. |
[12] | ZHOU Mi, SHEN Ruojian, WU Weiyun, YAN Hongmei, GUO Wei, PAN Baishen, WANG Beili. Performance evaluation and clinical application of 1,5-anhydrous sorbitol determination by enzymatic method [J]. Laboratory Medicine, 2019, 34(11): 1015-1020. |
[13] | ZHANG Shaohong, SHEN Xuebin. CYP2C19 gene polymorphism in the drug therapy of coronary heart disease [J]. Laboratory Medicine, 2018, 33(11): 979-982. |
[14] | FENG Renfeng. Standardization for the determination of lipoprotein(a) [J]. Laboratory Medicine, 2017, 32(7): 555-560. |
[15] | QIAO Rui, ZHANG Jie. Lipoprotein (a):a vital member of blood lipid items [J]. Laboratory Medicine, 2017, 32(7): 561-565. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||